GB8804188D0
(en)
*
|
1988-02-23 |
1988-03-23 |
Croda Int Plc |
Pharmaceutical compositions
|
US5407957A
(en)
*
|
1990-02-13 |
1995-04-18 |
Martek Corporation |
Production of docosahexaenoic acid by dinoflagellates
|
EP0457950B1
(fr)
*
|
1990-05-23 |
1993-10-20 |
Societe Des Produits Nestle S.A. |
Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires
|
GB9012651D0
(en)
*
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
BR9205526A
(pt)
*
|
1991-01-24 |
1994-04-19 |
Martek Corp Sociedade Norte Am |
Misturas de oleos microbianos e usos dos mesmos
|
CA2151820C
(en)
*
|
1993-01-15 |
2000-11-28 |
Stephen Joseph Demichele |
Structured lipids
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
US5411988A
(en)
*
|
1993-10-27 |
1995-05-02 |
Bockow; Barry I. |
Compositions and methods for inhibiting inflammation and adhesion formation
|
US5840715A
(en)
*
|
1995-12-11 |
1998-11-24 |
Inholtra Investment Holdings & Trading, N.V. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
CA2240165A1
(en)
*
|
1995-12-11 |
1997-06-19 |
Inholtra, Inc. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
DE19629433A1
(de)
*
|
1996-07-22 |
1998-01-29 |
Hoechst Ag |
Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
|
US5968809A
(en)
*
|
1997-04-11 |
1999-10-19 |
Abbot Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US5972664A
(en)
*
|
1997-04-11 |
1999-10-26 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US7745694B1
(en)
|
1997-04-11 |
2010-06-29 |
Monsanto Technology Llc |
Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
|
US6075183A
(en)
*
|
1997-04-11 |
2000-06-13 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US6051754A
(en)
*
|
1997-04-11 |
2000-04-18 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US6180671B1
(en)
*
|
1998-03-10 |
2001-01-30 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
|
US6136795A
(en)
*
|
1998-11-18 |
2000-10-24 |
Omni Nutraceuticals, Inc |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
WO2001051598A1
(en)
|
2000-01-11 |
2001-07-19 |
Monsanto Technology Llc |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
EP1406641B1
(en)
*
|
2001-06-18 |
2009-01-07 |
Neptune Technologies & Bioressources Inc. |
Krill extracts for prevention and/or treatment of cardiovascular diseases
|
WO2004091603A1
(fr)
*
|
2003-04-07 |
2004-10-28 |
Clinigenetics |
Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
|
US8633247B2
(en)
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Method for decreasing cartilage damage in dogs
|
US8633246B2
(en)
*
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Omega-3 fatty acids for osteoarthritis
|
US8075910B2
(en)
*
|
2004-05-20 |
2011-12-13 |
Pbm Pharmaceuticals, Inc. |
Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
|
WO2006056293A1
(en)
*
|
2004-11-29 |
2006-06-01 |
Unilever Plc |
Oral composition for enhancing skin properties
|
US20060286199A1
(en)
*
|
2005-06-03 |
2006-12-21 |
Marilou Laprise |
Method and composition for increasing omega-3 lipid in milk
|
PL2004160T3
(pl)
*
|
2006-04-12 |
2013-02-28 |
Unilever Nv |
Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
|
ES2391305T3
(es)
*
|
2006-04-12 |
2012-11-23 |
Unilever N.V. |
Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
|
US20080058418A1
(en)
*
|
2006-09-06 |
2008-03-06 |
The Coca-Cola Company |
Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
|
US20090018186A1
(en)
*
|
2006-09-06 |
2009-01-15 |
The Coca-Cola Company |
Stable beverage products comprising polyunsaturated fatty acid emulsions
|
DE102007055344A1
(de)
*
|
2007-11-19 |
2009-05-20 |
K. D. Pharma Bexbach Gmbh |
Neue Verwendung von Omega-3-Fettsäure(n)
|
EP3578177A1
(en)
|
2008-09-02 |
2019-12-11 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
PT2395991E
(pt)
|
2009-02-10 |
2013-09-03 |
Amarin Pharmaceuticals Ie Ltd |
Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia
|
EP2405902B1
(en)
*
|
2009-03-09 |
2021-07-21 |
Basf As |
Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
|
MX2011010821A
(es)
|
2009-04-17 |
2012-01-20 |
Cela Vista Pharmaceuticals Ltd |
Composiciones ricas en acidos grasos omega-3 con bajo contenido en acido fitanico.
|
NZ789295A
(en)
|
2009-04-29 |
2024-02-23 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
NZ627238A
(en)
|
2009-04-29 |
2016-02-26 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition comprising ethyl eicosapentaenoate
|
CN114053258A
(zh)
|
2009-06-15 |
2022-02-18 |
阿马里纳药物爱尔兰有限公司 |
在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
KR101204748B1
(ko)
*
|
2009-12-17 |
2012-11-26 |
(주) 켐포트 |
고도 불포화 지방산을 고농도로 함유하는 트리글리세라이드 유지의 제조방법
|
US20130137767A1
(en)
*
|
2010-02-02 |
2013-05-30 |
Dsm Ip Assets B.V. |
Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
|
US20140004186A1
(en)
*
|
2010-09-08 |
2014-01-02 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
|
NZ778131A
(en)
|
2010-11-29 |
2023-03-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
BR112014016788A8
(pt)
|
2012-01-06 |
2017-07-04 |
Chrysalis Pharma Ag |
composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
EP2846779A4
(en)
|
2012-05-07 |
2015-12-16 |
Omthera Pharmaceuticals Inc |
STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
|
JP2015522029A
(ja)
|
2012-06-29 |
2015-08-03 |
アマリン ファーマシューティカルス アイルランド リミテッド |
スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
CN112218630A
(zh)
|
2018-09-24 |
2021-01-12 |
阿马里纳药物爱尔兰有限公司 |
降低受试者的心血管事件的风险的方法
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|